SRR1477615
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.450
- INFLAMMATORY_RESPONSE+0.425
- KRAS_SIGNALING_DN+0.381
- ANGIOGENESIS+0.372
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.367
- COAGULATION+0.352
- PANCREAS_BETA_CELLS+0.351
- IL6_JAK_STAT3_SIGNALING+0.320
- MYOGENESIS+0.314
- APICAL_SURFACE+0.290
Top 10 suppressed
- DNA_REPAIR-0.527
- OXIDATIVE_PHOSPHORYLATION-0.518
- PROTEIN_SECRETION-0.515
- MYC_TARGETS_V1-0.486
- MYC_TARGETS_V2-0.387
- ANDROGEN_RESPONSE-0.338
- E2F_TARGETS-0.324
- MITOTIC_SPINDLE-0.324
- CHOLESTEROL_HOMEOSTASIS-0.301
- ADIPOGENESIS-0.275
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1378841 | GTEX | — | 0.982 |
| 2 | SRR602271 | GTEX | — | 0.971 |
| 3 | SRR1414424 | GTEX | — | 0.939 |
| 4 | BS_YG0A13JH | pilocytic astrocytoma | — | 0.935 |
| 5 | SRR1316392 | GTEX | — | 0.932 |
| 6 | SRR601787 | GTEX | — | 0.929 |
| 7 | SRR1336548 | GTEX | — | 0.926 |
| 8 | SRR1429162 | GTEX | — | 0.923 |
| 9 | MDT-AP-1108 | Med | Medulloblastoma | 0.923 |
| 10 | SRR1352706 | GTEX | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.425 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.381 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.372 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.367 | Inavolisib | — uncovered |
| COAGULATION | 0.352 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.351 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.314 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.255 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.243 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.224 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.214 | Inavolisib | — uncovered |
| COMPLEMENT | 0.208 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.191 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.175 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.165 | Inavolisib | — uncovered |
| APOPTOSIS | 0.131 | Idelalisib | — uncovered |